Craig M. Crews, Ph.D. (born June 1, 1964) is an American scientist at Yale University. As the Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology, Crews also holds joint appointments in the departments of Chemistry and Pharmacology. He currently serves as an Editor of Cell Chemical Biology and is the Executive Director of the Yale Center for Molecular Discovery. His research interests focus on Chemical Biology, particularly on controlled proteostasis, which has led to the development of the FDA approved anti-cancer drug Carfilzomib (Kyprolis®).

Property Value
dbo:abstract
  • Craig M. Crews, Ph.D. (born June 1, 1964) is an American scientist at Yale University. As the Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology, Crews also holds joint appointments in the departments of Chemistry and Pharmacology. He currently serves as an Editor of Cell Chemical Biology and is the Executive Director of the Yale Center for Molecular Discovery. His research interests focus on Chemical Biology, particularly on controlled proteostasis, which has led to the development of the FDA approved anti-cancer drug Carfilzomib (Kyprolis®). (en)
  • Craig M. Crews, Ph.D. (born June 1, 1964) is an American scientist at Yale University. He is the John C. Malone Professor of Molecular, Cellular, and Developmental Biology, and also holds joint appointments in the departments of Chemistry and Pharmacology. Crews is a former Editor of Cell Chemical Biology and the Executive Director of the Yale Center for Molecular Discovery. His research interests focus on Chemical Biology, particularly on controlled proteostasis. Crews has been a pioneer in the field of Targeted Protein Degradation and his lab's research led to the development of the FDA approved anti-cancer drug Carfilzomib (Kyprolis®). (en)
dbo:academicDiscipline
dbo:almaMater
dbo:award
dbo:birthDate
  • 1964-06-01 (xsd:date)
dbo:knownFor
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2020-02-14 04:36:58Z (xsd:date)
  • 2020-05-12 04:49:58Z (xsd:date)
  • 2020-05-12 18:28:12Z (xsd:date)
  • 2020-06-20 20:41:57Z (xsd:date)
  • 2020-07-30 07:23:37Z (xsd:date)
  • 2020-10-19 15:19:42Z (xsd:date)
  • 2020-10-27 09:19:32Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 50342947 (xsd:integer)
dbo:wikiPageLength
  • 14284 (xsd:integer)
  • 16954 (xsd:integer)
  • 16976 (xsd:integer)
  • 16992 (xsd:integer)
  • 17225 (xsd:integer)
  • 17289 (xsd:integer)
dbo:wikiPageModified
  • 2020-02-14 04:36:55Z (xsd:date)
  • 2020-05-12 04:49:53Z (xsd:date)
  • 2020-05-12 18:28:07Z (xsd:date)
  • 2020-06-20 20:41:51Z (xsd:date)
  • 2020-07-30 07:23:32Z (xsd:date)
  • 2020-10-19 15:19:37Z (xsd:date)
  • 2020-10-27 09:19:27Z (xsd:date)
dbo:wikiPageOutDegree
  • 66 (xsd:integer)
  • 70 (xsd:integer)
dbo:wikiPageRevisionID
  • 940717277 (xsd:integer)
  • 956221168 (xsd:integer)
  • 956320066 (xsd:integer)
  • 963618703 (xsd:integer)
  • 970259473 (xsd:integer)
  • 984331326 (xsd:integer)
  • 985680339 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Craig M. Crews, Ph.D. (born June 1, 1964) is an American scientist at Yale University. As the Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology, Crews also holds joint appointments in the departments of Chemistry and Pharmacology. He currently serves as an Editor of Cell Chemical Biology and is the Executive Director of the Yale Center for Molecular Discovery. His research interests focus on Chemical Biology, particularly on controlled proteostasis, which has led to the development of the FDA approved anti-cancer drug Carfilzomib (Kyprolis®). (en)
  • Craig M. Crews, Ph.D. (born June 1, 1964) is an American scientist at Yale University. He is the John C. Malone Professor of Molecular, Cellular, and Developmental Biology, and also holds joint appointments in the departments of Chemistry and Pharmacology. Crews is a former Editor of Cell Chemical Biology and the Executive Director of the Yale Center for Molecular Discovery. His research interests focus on Chemical Biology, particularly on controlled proteostasis. Crews has been a pioneer in the field of Targeted Protein Degradation and his lab's research led to the development of the FDA approved anti-cancer drug Carfilzomib (Kyprolis®). (en)
rdfs:label
  • Craig M. Crews (en)
foaf:gender
  • male (en)
foaf:isPrimaryTopicOf
foaf:name
  • Craig M. Crews (en)
owl:sameAs
is dbo:foundedBy of
is foaf:primaryTopic of